Allakos Inc Cash Flow Conversion Efficiency
Allakos Inc cash flow conversion efficiency. Based on the latest financial reports, Allakos Inc (ALLK) has a cash flow conversion efficiency ratio of -0.511x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.36 Million) by net assets ($55.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Allakos Inc (2016–2024)
Cash flow conversion efficiency of Allakos Inc from 2016 to 2024. This chart illustrates how Allakos Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Allakos Inc stock price for real-time trading data and today's change.
Allakos Inc Cash Flow Conversion Ratio Explained
Allakos Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Allakos Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allakos Inc ranked by their cash flow conversion efficiency. Also see market value of Allakos Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Axita Cotton Limited
NSE:AXITA
|
-0.008x |
|
Auric Mining Ltd
AU:AWJ
|
0.143x |
|
DIGITAL WORKFORCE SRV.EO1
F:DQ4
|
0.005x |
|
Inbest Prime I Inmuebles SOCIMI S.A.
MC:YINB1
|
N/A |
|
QT Imaging Holdings, Inc. Common Stock
NASDAQ:QTI
|
-2.154x |
|
Imperial Equities Inc.
V:IEI
|
0.026x |
|
Cpt Drives & Power Pcl
BK:CPT
|
-0.152x |
|
Wiseway Group Ltd
AU:WWG
|
0.271x |
Annual Cash Flow Conversion Efficiency for Allakos Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Allakos Inc from 2016 to 2024. Review Allakos Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $78.82 Million | $-93.62 Million | -1.188x | -72.16% |
| 2023-12-31 | $168.82 Million | $-116.48 Million | -0.690x | +23.49% |
| 2022-12-31 | $310.43 Million | $-279.97 Million | -0.902x | -93.29% |
| 2021-12-31 | $445.48 Million | $-207.85 Million | -0.467x | -168.01% |
| 2020-12-31 | $654.39 Million | $-113.92 Million | -0.174x | -36.96% |
| 2019-12-31 | $495.72 Million | $-63.01 Million | -0.127x | +39.17% |
| 2018-12-31 | $183.99 Million | $-38.45 Million | -0.209x | -154.42% |
| 2017-12-31 | $-58.77 Million | $-22.57 Million | 0.384x | -20.40% |
| 2016-12-31 | $-36.44 Million | $-17.58 Million | 0.482x | -- |
About Allakos Inc
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.